Mulpleta FDA Approval History
FDA Approved: Yes (First approved July 31, 2018)
Brand name: Mulpleta
Generic name: lusutrombopag
Dosage form: Tablets
Company: Shionogi Inc.
Treatment for: Thrombocytopenia
Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.
Development timeline for Mulpleta
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
